# **Coronavirus Disease 2019 (COVID-19) Situation Report**

Data as reported by national authorities by 24:00 local time 20 January 2021

## Situation Report No. 219 - Kingdom of Bahrain

21<sup>th</sup> of January, 2021



	Gl	obal	Eastern Mediterranean Region				
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths			
Total	94,963,847	2,050,857	5,408,924	129,171			
New	496,206	12,933	24,991	473			

#### **Kingdom of Bahrain**

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	98,573	95,240	366	2,967	13	2,584,657
New	313	303	4	-	-	10,782

## **HIGHLIGHTS**


The mortality were: 4 Bahraini citizens (2 female( 58 and 85 years old) and 2 male (76 and 81 years old)).
 Increasing number of citizens and residents continue to take COVD-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 20 January 2021 is 144,130.
 MOH urged people who have taken the first dose of COVID-19 vaccine to schedule to receive the second dose in 21 days.
 MOH Undersecretary highlighted the importance of continued and full adherence to public health measures, warning that the virus is still active and complicancy endangers the community.
 MOH Undersecretary negatings the community.
 MOH Undersecretary relative that the Virus is still active and complicancy and that 18% of cases registered are children under 17 years.
 MOH Undersecretary revealed that the MOH will confinue to conduct health compliance, is coordination with relevant authorities, on restarurants, cifet, source shore childre to avercisen yourds. Furgers.
 MOH Undersecretary indicated that molie vaccination units have been launched to provide COVID-19 vaccinations to the elderly and people with special needs, provides, provides growting were envired.
 Notional Taskforce for Combating the Coronavirus (NTCC) announced that Bahrain is ranked third internationally in terms of vaccinations rate (at approximate) & 44%.

With Special Index, proceeding the Consultance (NTCC) announced that Bahrain is ranked third internationally in terms of vaccinations rate (at approximately 8.4%).
National Taskforce for Combating the Consultance (NTCC) announced that Bahrain is ranked third internationally in terms of vaccinations rate (at approximately 8.4%).
NTCC highlighted the importance of individuals, who have been in contact with active cases, to wait for the authorities to contact them and not to rasch out directly to the testing units.
WHO: Encoding to non-communicable diseases during and beyond the COVD-19 gardiament; see link below.
WHO: Encoding to non-communicable diseases during and beyond the COVD-19 gardiament; see link below.
WHO: Encoding to non-communicable diseases during and beyond the COVD-19 gardiament; see link below.
WHO: Encoding durina con Alargene detection in the diagonsis of SARS-COV-21 Infection using rapidimmun oassay; see link below.
WHO: Encoding durina con Alargene detection in the diagonsis of SARS-CoV-21 Infection using rapidimmun oassay; see link below.
WHO: Encoding durina con Alargene tosts, therapeutic, vaccine radiness, and other health products for COVD-19 gase link below.
WHO: Encoding durina con Alargene tosts, therapeutic, vaccine radiness, and other health products for COVD-19 pace horizontal during the below.
WHO: Encoding durina con Alargene tosts, therapeutic, and therapeutic link below.
WHO: Encoding durina con Alargene tosts, therapeutic, encoding during during

subnational decision-makers; see link below. VMIO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19; see link below. VMIO: Scientistis tacle vaccine safety, efficacy and access at global R&D forum; see link below. VMIO: Emergency Committee on COVID-19 advices on varianity, scanceins; see link below. VMIO: Statement on the sixth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) panetemics; see link below.

#### **IMPORTANT LINKS**


<ul> <li>WHO's COVID-19 week</li> </ul>	r												
https://www.who.int/docs			tuation-report	s/20200	1817-weekly-epi	update	1.pdf?sfvrsn=	b6d49a76_4					
<ul> <li>WHO's COVID-19 Dashb</li> </ul>	oard: https://covid	119.who.int/											
· WHO: New research he	lps to increase und	lerstanding o	f the impact o	of COVID	19 for pregnan	t wome	n and their b	abies:					
https://www.who.int/new									gnant-	vomen-and	l-their-bab	ies	
• WHO: Responding to no	on-communicable o	diseases duri	ng and beyond	d the CO	VID-19 pandem	nic:http	s://bit.ly/2Sv	ds0r					
<ul> <li>WHO :Emergency Globa</li> </ul>	al Supply Chain Sys	tem(COVID-1	L9) catalogue:										
https://www.who.int/pub	lications/i/item/em	ergency-glob	al-supply-chair	n-system	n-(covid-19)-cata	logue							
•WHO: Interim guidance	on Antigen-detecti	ion in the dia	gnosis of SARS	S-CoV-2	infection using	rapidim	mun oassays	:bit.ly/2lfOjVF					
<ul> <li>WHO SAGE values frame</li> </ul>	ework for the alloc	ation and pri	oritization of C	OVID-1	9 vaccination :b	it.ly/2J0	wxWQ						
<ul> <li>WHO: Interim guidance</li> </ul>	e on Diagnostics, t	herapeutics,	vaccine reading	ness, an	d other health	produc	s for COVID-	19: https://www	.who.i	nt/publicati	ions/i/item	WHO-20	9-nCoV
HCF_assessment-Products	-2020.1												
<ul> <li>WHO: Checklist</li> </ul>		schools	re-opening	and	preparation	for	COVID-19	resurgences	or	similar	public	health	crises
https://www.who.int/pub	lications/i/item/978	89240017467											
<ul> <li>COVID-19 vaccine introd</li> </ul>	Juction and deploy	mentcosting	tool: https://v	www.wh	o.int/publication	ns/i/iter	n/106653375	53					
WHO: Emergency Use D	esignation of COVI	D-19 candida	te vaccines: Et	thical co	nsiderations for	current	and future C	OVID-19placebo	-contr	olled vaccir	e trials an	d trial unb	inding:
https://www.who.int/pub	lications/i/item/WI	HO-2019-nCa	V-Policy_Brief-	EUD_pla	acebo-controller	d_vaccir	e_trials-2020	.1					
• WHO: Risk assessment t	cool to inform mitig	ation measu	res for interna	tional tr	ravel in the cont	ext of C	OVID-19:						
https://www.who.int/pub	lications/i/item/WH	IO-2019-nCo	V-Risk-based_in	nternatio	onal_travel-Asse	ssment	tool-2020.1						
• WHO: COVAX Announce	es additional deals	to access pro	mising COVID-	19 vacci	ine candidates;	plans gl	obal rollout st	tarting Q1 2021:					
https://www.who.int/new	rs/item/18-12-2020	-covax-annou	inces-additiona	al-deals-	to-access-promi	sing-cov	id-19-vaccine	-candidates-plar	s-globa	I-rollout-st	arting-q1-2	2021	
<ul> <li>WHO issues its first emo</li> </ul>	ergency use validati	ion for a COV	ID-19 vaccine	and emi									
<ul> <li>wno issues its first eme</li> </ul>					phasizes need for	or equit	able global ac	cess:					
		-who-issues-i	ts-first-emerge						ed-for-	equitable-g	lobal-acce	55	
https://www.who.int/new	rs/item/31-12-2020			ency-use	-validation-for-a	-covid-1	9-vaccine-an		ed-for-	equitable-g	lobal-acce	55	
https://www.who.int/new • WHO: Genomic sequent	s/item/31-12-2020 cing of SARS-CoV-2	a guide to in	nplementation	ency-use	-validation-for-a	-covid-1	9-vaccine-an		ed-for-	equitable-g	lobal-acce	55	
https://www.who.int/new • WHO: Genomic sequent https://www.who.int/pub	rs/item/31-12-2020 cing of SARS-CoV-2 lications/i/item/978	a guide to in 89240018440	nplementation	ncy-use	validation-for-a ximum impact o	n publi	9-vaccine-and chealth:	d-emphasizes-ne	ed-for-	equitable-g	lobal-acce	55	
<ul> <li>https://www.who.int/new</li> <li>WHO: Genomic sequent</li> <li>https://www.who.int/pubie</li> <li>WHO: Interim recommendation</li> <li>https://www.who.int/pubie</li> </ul>	rs/item/31-12-2020 cing of SARS-CoV-2 lications/i/item/978 endations for use of lications/i/item/WH	a guide to in 89240018440 f the Pfizer-B 10-2019-nCo <sup>1</sup>	ioNTech COVII	ncy-use n for ma D-19 vac SE_recor	-validation-for-a ximum impact c ccine, BNT162b2 nmendation-BN	-covid-1 on publi 1, under T162b2	9-vaccine-and c health: Emergency U	d-emphasizes-ne	ed-for-	equitable-g	lobal-acce	55	
<ul> <li>https://www.who.int/new</li> <li>WHO: Genomic sequent</li> <li>https://www.who.int/pub</li> <li>WHO: Interim recomme</li> <li>https://www.who.int/pub</li> <li>WHO: Global scientists</li> </ul>	rs/item/31-12-2020 cing of SARS-CoV-2: lications/i/item/978 indations for use of lications/i/item/WH double down on SA	a guide to in 89240018440 f the Pfizer-B 10-2019-nCo IRS-CoV-2 van	ioNTech COVII -vaccines-SAG	ncy-use for ma D-19 vac SE_recor at WHC	validation-for-a ximum impact o ccine, BNT162b2 nmendation-BN D-hosted forum	-covid-1 on publi , under T162b2	9-vaccine-and c health: Emergency U 2021.1	d-emphasizes-ne Ise Listing:	ed-for-	equitable-g	lobal-acce	55	
https://www.who.int/new • WHO: Genomic sequent https://www.who.int/pub • WHO: Interim recomme https://www.who.int/pub • WHO: Global scientists ( https://www.who.int/new	rs/item/31-12-2020 cing of SARS-CoV-2 lications/i/item/978 andations for use of lications/i/item/WH double down on SA rs/item/12-01-2021	a guide to in 89240018440 f the Pfizer-B 40-2019-nCo <sup>1</sup> uRS-CoV-2 van -global-scient	nplementation ioNTech COVII /-vaccines-SAG riants research tists-double-do	D-19 vac b for ma D-19 vac bE_recor a at WHC iwn-on-s	validation-for-a ximum impact o ccine, BNT162b2 nmendation-BN D-hosted forum cars-cov-2-variar	-covid-: on publi , under T162b2 its-rese	9-vaccine-and c health: Emergency U 2021.1 arch-at-who-h	d-emphasizes-ne Ise Listing: iosted-forum			lobal-acce	55	
https://www.who.int/new • WHO: Genomic sequenn https://www.who.int/pub • WHO: Interim recomme https://www.who.int/pub • WHO: Global scientists 4 https://www.who.int/new • WHO: Draft landscape of WHO: Draft landscape of	rs/item/31-12-2020 cing of SARS-CoV-2 lications/i/item/978 indations for use of lications/i/item/WH double down on SA ss/item/12-01-2021 of COVID-19 candid	a guide to ir 89240018440 f the Pfizer-B 10-2019-nCo <sup>1</sup> IRS-CoV-2 van -global-scient late vaccines	nplementation ioNTech COVII /-vaccines-SAG riants research tists-double-do : https://www.	D-19 vad E_recor at WHC wn-on-s who.int	validation-for-a ximum impact o ccine, BNT162b2 mmendation-BN D-hosted forum iars-cov-2-variar /publications/m,	r-covid-: on publi t, under T162b2 its-reses /item/di	9-vaccine-and c health: Emergency U 2021.1 arch-at-who-h aft-landscape	d-emphasizes-ne Ise Listing: ⊨osted-forum ⊨of-covid-19-can	didate	vaccines			
https://www.who.int/new • WHO: Genomic sequen https://www.who.int/pub • WHO: Interim recomme https://www.who.int/pub • WHO: Global scientists o https://www.who.int/new • WHO: Draft landscape o • WHO: Analysing and us	rs/item/31-12-2020 cing of SARS-CoV-2: lications/i/item/978 indations for use of lications//item/WH double down on SA rs/item/12-01-2021 of COVID-19 candid ing routine data to	a guide to ir 89240018440 f the Pfizer-B 10-2019-nCo' IRS-CoV-2 var -global-scient late vaccines monitor the	ioNTech COVII /-vaccines-SAG riants research tists-double-do - https://www. effects of COV	D-19 vad SE_record at WHC wn-on-st who.int; /ID-19 of	validation-for-a ximum impact o cone, BNT162b2 mmendation-BN D-hosted forum iars-cov-2-variar /publications/m, n essential healt	-covid-: on publi 2, under T162b2 its-reses /its-reses /item/di th servi	9-vaccine-and c health: Emergency U 2021.1 urch-at-who-h aft-landscape ces: practical p	d-emphasizes-ne Ise Listing: ⊨osted-forum ⊨of-covid-19-can	didate	vaccines			
https://www.who.int/new wtb2: Genomic sequeni https://www.who.int/pub wtHO: Interim recomme https://www.who.int/pub wtHO: Global scientists https://www.who.int/new wtHO: Draft landscape ( wtHO: Analysing and us https://www.who.int/pub	rs/item/31-12-2020 cing of SARS-CoV-2: lications//item/978 andations for use of lications//item/WH double down on SA sc/item/12-01-2021 of COVID-19 candid ing routine data to lications//item/WH	a guide to ir 39240018440 f the Pfizer-B 40-2019-nCo' <b>RS-CoV-2</b> var- global-scient late vaccines monitor the 40-2019-nCo'	ioNTech COVII /-vaccines-SAG riants research tists-double-do - https://www. effects of COV /-essential_hes	D-19 vad be for ma D-19 vad be record at WHO with on-s who.int, /ID-19 of alth_ser	validation-for-a ximum impact of cone, BNT162b2 mmendation-BN D-hosted forum iars-cov-2-variar /publications/m, n essential heal vices-monitorinj	tovid-: on public , under T162b2 its-reses fitem/di th servic z-2021.:	9-vaccine-and c health: Emergency U 2021.1 urch-at-who-h aft-landscape ces: practical p	d-emphasizes-ne Ise Listing: ⊨osted-forum ⊨of-covid-19-can	didate	vaccines			
https://www.who.int/new * WHO: Genomic sequen https://www.who.int/pub * WHO: Interim recomme https://www.who.int/pub * WHO: Global scientists - wHO: Draft landscape * WHO: Analysing and us https://www.who.int/pub	rs/item/31-12-2020 cing of SARS-CoV-2: lications/l/item/978 indations for use of lications/l/item/WH double down on SA s/item/12-01-2021 of COVID-19 candid ing routine data to lications/l/item/WH wment on mRNA va	a guide to ir 39240018440 f the Pfizer-B 40-2019-nCo' <b>RS-CoV-2</b> var -global-scient late vaccines monitor the 40-2019-nCo' ccine BNT162	ioNTech COVII /-vaccines-SAG riants research hists-double-do - https://www. effects of COV /-essential_he: 2b2 (Pfizer-Bio	ency-use a for ma D-19 vac GE_recor a at WHO swn-on-s who.int; /ID-19 or alth_ser NTech) :	validation-for-a ximum impact of corine, BNT162b2 nmendation-BN D-hosted forum iars-cov-2-variar (publications/m) n essential heaving vices-monitoring against COVID-1	covid-: en publi , under T162b2 its-rese its-res	9-vaccine-ani c health: Emergency U 2021.1 arch-at-who-h aft-landscape ess: practical p	d-emphasizes-ne Ise Listing: nosted-forum ⊱of-covid-19-can guide for nation:	didate	vaccines			
https://www.who.int/new wH02 Genomic sequen https://www.who.int/pub wH02 Interim recomme https://www.who.int/pub wH03 Global scientists wH05 Craft landscape ( wH02 Craft landscape ( wH02 MayJung and us https://www.who.int/pub wH02 Background docc https://www.who.int/pub	rs/item/31-12-2020 cing of SARS-CoV-2: lications/l/item/978 indations for use of lications/l/item/WH double down on SA rs/item/12-01-2021 of COVID-19 candid ing routine data to lications/l/item/WH ument on mRNA va lications/l/item/bac	a guide to ir 39240018440 F the Pfizer-B 40-2019-nCo <sup>1</sup> <b>RS-CoV-2</b> var- global-scient late vaccines monitor the 40-2019-nCo <sup>1</sup> ciccine BNT162 ckground-doc	ioNTech COVII V-vaccines-SAG iants research tists-double-do https://www. effects of COV V-essential_he: 2b2 (Pfizer-Bio ument-on-mrm	ency-use a for ma D-19 vac GE_recor a at WHC rwn-on-s who.int; /ID-19 or alth_ser NTech) : ra-vaccin	validation-for-a ximum impact of ximum impact of ximendation-BN 3-hosted forum ars-cov-2-variar /publications/m, n essential heal vices-monitoring against COVID-3 e-bnt162b2-(pf	covid-: en publi , under T162b2 its-rese its-res	9-vaccine-ani c health: Emergency U 2021.1 arch-at-who-h aft-landscape ess: practical p	d-emphasizes-ne Ise Listing: nosted-forum ⊱of-covid-19-can guide for nation:	didate	vaccines			
https://www.who.int/new wthci.or.Genomic sequene wthci.or.Genomic sequene wthci.interim recomme wthci.interim recomme wthci.interim recomme wthci.interim recomme wthci.interim landscape wthci.interim landscape wt	rs/item/31-12-2020 cing of SARS-CoV-2: lications///item/978 modations for use of lications//item/WH double down on SA sy/item/12-01-2021 of COVID-19 candidi ling routine data to lications//item/WH ument on mRNA va lications//item/bac	a guide to ir 39240018440 F the Pfizer-B 40-2019-nCo <sup>1</sup> RS-CoV-2 var -global-scient ste vaccines - monitor the 40-2019-nCo <sup>1</sup> ciccine BNT162 ckground-doc cacy and acce	nplementation ioNTech COVII -vaccines-SAG inants research ists-double-do https://www. effects of COV /-essential_he: 2b2 (Pfizer-Bio ument-on-mm sss at global R8	ency-use a for ma D-19 vac GE_recor a at WHC wn-on-s who.int; /ID-19 or alth_ser NTech) : ia-vaccin &D forus	validation-for-a ximum impact of xine, BNT162b2 mmendation-BN D-hosted forum aras-cov-2-variar (publications/m, nessential heal vices-monitoring against COVID-1 against COVID-1 m:	-covid-: on publi t, under T162b2 its-reses fitem/di th servi g-2021.: 9: izer-bio	9-vaccine-ani chealth: 2021.1 arch-at-who-h aft-landscape ses: practical p atech)-against	d-emphasizes-ne Ise Listing: nosted-forum ⊱of-covid-19-can guide for nation:	didate	vaccines			
https://www.who.int/new + WHO: Genomic sequenn https://www.who.int/pub + WHO: literim recomme + WHO: literim recomme + WHO: Global scientists + WHO: Analysho.int/new + WHO: Draft landscape + WHO: Moling and us https://www.who.int/pub + WHO: Scientist stackle + WHO: Scientist stackle	ss/item/31-12-2020 cing of SARS-CoV- lications//item/978 indations for use of double down on SA ss/item/WH double down on SA ss/item/VH-10-2021 of COVID-19 candid ing routine data to lications//item/WH- ment on mRNA va lications//item/VH- vaccine safety, effili s/item/16-01-2021	a guide to ir 89240018440 f the Pfizer-B 40-2019-nCo' IRS-CoV-2 val 	nplementation ioNTech COVII V-vaccines-SAG iants research hists-double-do https://www. effects of COV V-essential_her 2b2 (Pfizer-Bio ument-on-mm res at global R& ckle-vaccine-sa	ncy-use a for ma D-19 vac E_recor a at WHO wn-on-s who.int; /ID-19 or alth_ser NTech) : na-vaccin &D forus fety-effi	validation-for-a ximum impact of xine, BNT162b2 mmendation-BN D-hosted forum aras-cov-2-variar (publications/m, nessential heal vices-monitoring against COVID-1 are-bnt162b2-(pf m:	-covid-: on publi t, under T162b2 its-reses fitem/di th servi g-2021.: 9: izer-bio	9-vaccine-ani chealth: 2021.1 arch-at-who-h aft-landscape ses: practical p atech)-against	d-emphasizes-ne Ise Listing: nosted-forum ⊱of-covid-19-can guide for nation:	didate	vaccines			
https://www.who.int/new wHWO: Genowic sequen https://www.who.int/pub wHWO: Interim recomme https://www.who.int/pub wHWO: Cababa scientists wHWO: Anatyping and us https://www.who.int/pub wHWO: Background docu https://www.who.int/pub wHWO: Sackground docu https://www.who.int/pub wHWO: Sackground docu	s,/item/31-12-2020 cing of SARS-CoV-2: lications//item/978 endations for use of double down on SA ss/item/12-01-2021 of COVID-19 candid ing routine data to lications//item/WH ament on mRNA va lications//item/WH strem/16-01-2021 mittee on COVID-15	a guide to in 89240018440 f the Pfizer-B 40-2019-nCo' RS-CoV-2 var- -global-scient fate vaccines monitor the monitor the 0-2019-nCo' sciene BNT162 ckground-doc cacy and acce -scientists-ta- B advises on m	nplementation ioNTech COVII /-vaccines-SAG iants research tists-double-do https://www. effects of COV /-essential_he 2b2 (Pfizer-Bio ument-on-mr ess at global R& kole-vaccine-sa variants, vaccin	ency-use a for ma D-19 vac SE_recor a at WHO swn-on-s who.int; /ID-19 or alth_ser NTech) : sa-vaccin &D forus fety-effi tes:	validation-for-a ximum impact of coine, BNT162b3 nmendation-BN 3-hosted forum ars-cov-2-variar /publications/m, n essential heal vices-monitoring against COVID-3 ve-bnt162b2-(pf m: icacy-and-access	-covid-: en publi , under T162b2 its-rese: fitem/di th servic s-2021.: 9: izer-bior -at-glob	9-vaccine-ani chealth: Emergency U 2021.1 arch-at-who-h aft-landscape es: practical p attech)-against al-r-d-forum	d-emphasizes-ne Ise Listing: nosted-forum ⊱of-covid-19-can guide for nation:	didate	vaccines			
http://www.who.int/pub + WHO: Genomic sequen http://www.who.int/pub + WHO: Interim recomme + WHO: Interim recomme + WHO: Calshal scientists + WHO: Calshal scientists + WHO: Background doc. https://www.who.int/pub + WHO: Scientist tackle + WHO: Emergency Com + WHO: Emergency Com	s/item/31-12-2020 cling of SARS-CoV-2 lications/litem/378 incations/litem/378 incations/litem/WH double down on SA s/item/11-20-2021 lincations/litem/WH ument on mRNA va lications/litem/WH ument on mRNA va vaccine safety, effit s/item/16-01-2021 mittee on COVID-18 vac/item/16-01-2021	a guide to in 89240018440 f the Pfizer-B 40-2019-nCo' rglobal-scient fate vaccines monitor the 40-2019-nCo' cicle BNT162 ckground-doc cacy and acce -scientists-ta 9 advises on n 1-emergency-	nplementation ioNTech COVII /vaccines-SAG riants research rists-double-do https://www. effects of COV /vessential_hee 2b2 (Pfizer-Bio ument-on-mm ess at global R8 ckle-vaccine-sa variants, vaccin committee-on-	ncy-use a for ma D-19 vac SE_record a at WHC who-on-s who-int; /ID-19 or alth_ser NTech) : as-vaccin &D forus fety-effi nes: -covid-1!	validation-for-a ximum impact of terms and the second second D-hosted forum ars-cov-2-variar (publications/m, n essential heal vices-monitorin against COVID-3 se-bnt162b2-(pf m; cracy-and-access 9-advises-on-variantication (second-se	-covid-: en publi , under T162b2 its-rese: fitem/di th servir s-2021.: 9: izer-bior -at-glob riants-w	9-vaccine-ani c health: Emergency U 2021.1 urch-at-who-h aft-landscape xes: practical p atech)-against al-r-d-forum uccines	d-emphasizes-ne Ise Listing: •of-covid-19-can guide for nation: -covid-19	didate al and :	vaccines	l decision-	makers:	
https://www.who.int/new wHWO: Genowic sequen https://www.who.int/pub wHWO: Interim recomme https://www.who.int/pub wHWO: Cababa scientists wHWO: Anatyping and us https://www.who.int/pub wHWO: Background docu https://www.who.int/pub wHWO: Sackground docu https://www.who.int/pub wHWO: Sackground docu	r_item?i3:12:2:202 cing of SARS-CoV-2: lications/item?i3? incations/item?i3? incations/item?i4? double down on SA /item?i4:201-2021 of COVID-19 candid ling routine data to fications/item?i4? lications/item?i4? lications/item?i4? lications/item?i4? lications/item?i4? mittee on COVID-19 exist new file on the same sixt meeting of t	a guide to in 39240018440 F the Pfizer-B (0-2019-nCo' URS-CoV-2 var -global-scient late vaccines monitor the 40-2019-nCo' coine BNT162 ckground-doc cacy and acce -scientists-ta 3 advises on 1 -emergency- the Internatic	nplementation ioNTech COVII /vaccines-SAG riants research riants research rists-double-do - https://www. effects of COV /v-essential_hes bb2 (Pfizer-Bio ument-on-mrn ument-on-mrn ss at global R8 ckle-vaccine-sa variants, vaccin committee-on- snal Health Rej	ncy-use a for ma D-19 vac E_record a t WHC wm-on-s who.inty /ID-19 or alth_ser NTech) : ia-vaccint &D forum fety-effi tes: -covid-1! gulation	validation-for-a ximum impact c xcine, BNT162b3 3-hosted forum aras-cov-2-variar /publications/m, nessential heal vices-monitoring against COVID-3 he-bnt162b2-(pf m: acacy-and-access 9-advises-on-val s (2005) Emerge	-covid-: an publi t, under T162b2 its-resec fitem/di th servic s-2021: g-2021:	9-vaccine-ani chealth: Emergency U 2021.1 arch-at-who-h aft-landscape ses: practical j	d-emphasizes-ne lse Listing: +of-covid-19-can guide for nation: -covid-19	didate al and : virus d	vaccines aubnationa	l decision= /ID-19) pai	makers: ndemic:	8-



## Total Number of Cases







#### **IMPORTANT CONTACTS**

• The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAli5@health.gov.bh

• International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh